CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)

N/A

Report date: 2023/05/19 15:50:46

Base Information

Drug NameCXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMAC-X-C motif chemokine receptor 4 antagonists
TargetsB-cell maturation proteinC-X-C motif chemokine receptor 4
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A